Clinical Trial Update: Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating rasburicase to prevent graft-versus-host disease in patients undergoing donor stem cell transplantation; the study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Neoplasms

Drugs mentioned

• Rasburicase (rasburicase)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1 | Status: COMPLETED | Results posted: 2017-04-11